# Mozart Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mozart-therapeutics

- Industry: Biotechnology
- Headquarters: Seattle, US
- Website: www.mozart-tx.com
- Total disclosed funding: $80M
- Latest round: Series A (Jun 7, 2023)
- Investors on record: 11

## About

Based in Seattle, US, Mozart Therapeutics focuses on developing biologics aimed at restoring immune function in patients with autoimmune diseases through innovative CD8 Treg modulators.Founded in 2020, Mozart Therapeutics is dedicated to creating therapies for autoimmune conditions. The company raised USD 25.000 mn in Series A funding on June 7, 2023, with participation from investors such as Pfizer Venture Investments and AbbVie Biotech Ventures. Currently valued at USD 105.229 mn, Mozart has completed 2 deals to date, all centered around advancing their clinical pipeline.Mozart Therapeutics specializes in the development of innovative biologics targeting autoimmune diseases. Key offerings include first-in-class CD8 Treg modulators that address immune dysregulation. Their pipeline features candidates like MTX-101 and MTX-201, which are advancing through clinical development phases, serving healthcare providers and patients primarily in North America and Europe.Mozart Therapeutics generates revenue through partnerships and collaborations with research institutions, focusing on clinical development agreements that may include licensing and milestone payments. Direct sales of their therapies will engage healthcare facilities and pharmaceutical distributors, although specific pricing strategies remain undisclosed.Following the Series A funding of USD 25.000 mn raised in June 2023, Mozart Therapeutics plans to expand its product pipeline and advance clinical trials for MTX-101. The additional funding will facilitate the progression of their therapies and support further clinical development efforts, aligning with their goal of addressing unmet needs in the autoimmune disorder space.

## Funding rounds

- Series A, Jun 7, 2023, $25M — ARCH Venture Partners, Sofinnova Partners, Alexandria Venture Investments, Altitude Life Science Ventures, Pfizer Venture Investments, AbbVie Ventures, Eli Lilly & Company, UPMC Enterprises, MRL Ventures Fund, Leaps by Bayer, Ono Venture Investment
- Series A, Oct 26, 2021, $55M — ARCH Venture Partners, Sofinnova Partners, Alexandria Venture Investments, Altitude Life Science Ventures, Eli Lilly & Company, MRL Ventures Fund, Leaps by Bayer

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Altitude Life Science Ventures (https://capitalatlas.ai/funds/altitude-life-science-ventures) — Series A
- Eli Lilly & Company — Series A
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series A
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series A
- UPMC Enterprises (https://capitalatlas.ai/funds/upmc-enterprises) — Series A
- Ono Venture Investment (https://capitalatlas.ai/funds/ono-venture-investment) — Series A